Massachusetts Institute of Technology, Cambridge, MA, USA.
Smt. Kanuri Santhamma Centre for Vitreo-Retinal Diseases, L V Prasad Eye Institute, Hyderabad, Telangana, India.
Indian J Ophthalmol. 2021 Mar;69(3):666-670. doi: 10.4103/ijo.IJO_1538_20.
The aim of this study was to analyze the cost and factors affecting diabetic retinopathy (DR) care in a tertiary eye care facility in South India.
In a retrospective, observational study, we evaluated the costs incurred in DR management in each stage of retinopathy from electronic medical records. Both medical and indirect costs (transportation and boarding) were calculated.
The study evaluated 1000 consecutive patients (2000 eyes) with DR, from January to June 2019. One-third (32%; n = 321) patients were females. The median cost per patient was INR 8,214 (IQR 2,812-29,748). Cost of care was higher in patients with sight-threatening DR (STDR) compared to non-STDR (INR 31,820 vs INR 14,356, P < 0.001). Among 57.3% (n = 573;1137 eyes) of subjects who completed treatment, there was a statistically significant reduction in visual impairment (427 to 355 eyes) and blindness (<3/60) (132 to 103 eyes) from baseline (P < 0.001). The number of follow-up visits had a negative association with travel distance and socioeconomic status (P < 0.001); the positive association was seen with DR severity (P = 0.002) and total cost (P < 0.001) on regression analysis. There was a nearly 3-fold difference in the average medical cost per eye for subjects with severe visual loss (<3/60) (INR 26,270) compared to those with good vision (≥6/12) (INR 8,510).
Treatment of DR benefits, but the cost of care increases with disease severity and visual impairment. Compliance to care was related to DR severity and treatment cost. Some of the barriers could be reduced with greater advocacy and reduced travel distance.
本研究旨在分析印度南部一家三级眼科医疗机构中糖尿病视网膜病变(DR)治疗的成本和影响因素。
在一项回顾性观察研究中,我们从电子病历中评估了每个视网膜病变阶段的 DR 管理所产生的成本。计算了医疗和间接成本(交通和住宿)。
该研究评估了 2019 年 1 月至 6 月期间的 1000 例连续 DR 患者(2000 只眼)。三分之一(32%;n=321)的患者为女性。每位患者的平均费用为 8214 印度卢比(IQR 2812-29748)。与非威胁视力的 DR(非 STDR)相比,有威胁视力的 DR(STDR)患者的治疗费用更高(INR 31820 与 INR 14356,P<0.001)。在完成治疗的 57.3%(n=573;1137 只眼)患者中,视力损害(427 只眼至 355 只眼)和失明(<3/60)(132 只眼至 103 只眼)的比例从基线显著降低(P<0.001)。随访次数与旅行距离和社会经济地位呈负相关(P<0.001);与 DR 严重程度呈正相关(P=0.002),与总费用呈正相关(P<0.001)。回归分析显示,严重视力丧失(<3/60)(INR 26270)的患者每只眼的平均医疗费用几乎是视力良好(≥6/12)(INR 8510)的患者的 3 倍。
DR 的治疗有益,但随着疾病严重程度和视力损害的增加,治疗成本也会增加。对治疗的依从性与 DR 的严重程度和治疗费用有关。通过更多的宣传和减少旅行距离,可以减少一些障碍。